Dupilumab 300 mg 每两周一次用于过敏性真菌性鼻窦炎患者内镜鼻窦术后研究

数据集获取

源站：https://clinicaltrials.gov/study/NCT06461949

标准获取流程：

1. 访问源站链接，注册/登录账号；
2. 进入数据集详情页，按页面指引申请权限或直接下载；
3. 部分平台提供 SDK，例如：
   • OpenDataLab: pip install openxlab 后 openxlab.dataset.get(...)
   • ModelScope: pip install modelscope 后 modelscope download
   • 天池: 登录后页面提供直链下载
     以源站「数据下载/使用文档」页面为准。

数据说明

Conditions: Allergic Fungal Rhinosinusitis (AFRS), Chronic Rhinosinusitis (CRS), Asthma, Nasal Polyps. Study Description: Multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy of dupilumab to placebo in allergic fungal rhinosinusitis (AFRS) subjects after sinus surgery on a background treatment with intranasal corticosteroid spray. Study periods: The clinical trial consists of 4 periods: -Run-in period (2 weeks + 4 weeks): All participants will enter a run-in period of 2-6 weeks receiving saline irrigations and Intranasal Corticosteroids per the treating physician. All oral steroids and antibiotics will be stopped. -Ethmoid Tissue Collection period (7 days + 4 weeks): Participants will undergo surgery as scheduled per standard of care. Ethmoid tissue will be collected from all subjects at the time of surgery. -Randomized treatment (52 weeks +/- 7 days): Participants will be randomized to one of the following treatments: * Arm A: dupilumab 300 mg subcutaneous (SC) every two weeks for 52 weeks * Arm B: placebo given SC every two weeks for 52 weeks * Posttreatment period (12 weeks +/- 7 days): After completing 52 weeks of treatment with IMP (or following early discontinuation of IMP), subjects will be instructed to: * Return to the study site for the last scheduled visits for physical examination, nasal endoscopy, Nasal Polyps Score (NPS), Patient-Reported Outcomes (PROs)(Sinonasal Outcomes Test-SNOT-22-, and Asthma Control Questionnaire -ACQ-), FEV1 measurement in those with asthma, and safety. * Continue on stable dose of INCS spray during the posttreatment period. * Report any adverse event (AE). Co-Primary Objectives: * Determine the efficacy of dupilumab in controlling sinonasal inflammation and preventing nasal polyp recurrence after complete sinus surgery for AFRS as measured by change in the mLK score. * Evaluate the effect of dupilumab on oral corticosteroid utilization following complete sinus surgery for AFRS. Secondary Objectives: To evaluate the effect of dupilumab on: * Prevention of revision surgery for AFRS * Secondary ob

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。